← The patent line

Menthol; Methyl Salicylate

Sold as SALONPAS · given by topical

Three to five years until it comes off patent
3.4 yr
Until anyone may copy it
Protection runs to 2030-01-03
9
Trials running now
294 registered in total
In routine use
Furthest stage reached
already in routine clinical use
3
Organisations running trials
lead sponsors on record
01

Who owns it, and until when

Hisamitsu Pharmaceutical Co Inc
Approval holder
the only company permitted to sell it today
2030-01
Last patent expires
latest patent filed against this product
none listed
FDA exclusivity ends
a separate protection granted at approval

Whichever date falls later is when other manufacturers may apply to sell copies. Price typically falls steeply within a year of that point, and with it any company's ability to recover the cost of new research on the molecule. That is when it becomes a candidate for the ledger on the first tab.

02

What it is being tested for

SmokingTobacco UseTobacco Smoking
03

Who is paying for the research

RAI Services Company
Company
7
Philip Morris Products S.A.
Company
4
University of Minnesota
University or hospital
3

Who funds the trials matters after protection lapses. Company-funded work usually stops once exclusivity ends; university, hospital and government-funded work does not, and is the research most likely to continue on this molecule afterwards.

04

The trials themselves

NCT07604246No trials on record2026 · 25 people · not yet recruiting
Evaluating the Effect of Nicotine on Eye Mov

Expiry dates are what the patent holder has filed; litigation, paediatric extensions and settlements routinely move them, so read these as the earliest plausible date rather than a schedule. Not medical advice.

← Back to the patent line